All In MedTech

Device Trial Radar · NCT02139072

CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients

Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Mar 2015

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hoffmann-La Roche
First posted
May 15, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.

Conditions

  • Antiphospholipid Antibody Syndrome

Interventions

  • CoaguChek XSDevice

    CoaguChek XS will be used to measure INR in patients with APL

  • Standard Lab DrawProcedure

    Patients on warfarin for any indication other than APL will measure INR by venous lab draw

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. International Normalized Ratio (INR)Time frame: Day 1 and Day 60

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UF and Shands Health

    Gainesville, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.